Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Vilazodone generic available fda?

See the DrugPatentWatch profile for Vilazodone

Is there an FDA-approved vilazodone generic?

Vilazodone is marketed in the U.S. as Viibryd, and current FDA-approved “generic vilazodone” availability depends on whether the FDA has approved at least one abbreviated new drug application (ANDA) for vilazodone hydrochloride. The information you provided doesn’t include FDA product listings or approval status for generics, so I can’t confirm from it whether a vilazodone generic is FDA-approved or currently on the market.

How can I check the FDA status for a vilazodone generic?

To verify whether a generic vilazodone is FDA-approved, check the FDA’s drug approval databases for:
- ANDA approvals for “vilazodone” (or “vilazodone hydrochloride”)
- The Orange Book listing for Viibryd and any generic equivalents

These sources show whether an FDA-approved generic exists and whether it is considered substitutable (same active ingredient, strength, and dosage form).

Is vilazodone generic available at pharmacies even if FDA approval exists?

FDA approval is the first step. Even with an approved generic, pharmacies may still have limited stock based on distribution and current supply. The most reliable way to confirm real-world availability is to combine:
- FDA approval status (Orange Book), and
- Current pharmacy inventory or major online pharmacy listings.

What if there isn’t a generic yet—when might one appear?

Generic timelines depend on patent and exclusivity. If no generic ANDA is approved yet, it usually reflects active exclusivity or litigation. Without the specific patent/exclusivity status for vilazodone in your question context, I can’t provide a date.

Can I ask for the exact FDA listing I should look up?

If you tell me the strength and dosage form you need (for example, 10 mg, 20 mg, or 40 mg tablets), I can help you identify what the FDA Orange Book entry would look like to confirm whether a generic is approved for that exact product.

Quick clarification

Do you mean:
1) “Is any vilazodone generic FDA-approved in the U.S. right now?” or
2) “Is my specific Viibryd dose (10/20/40 mg tablet) available as a generic?”

If you answer with your dose (and whether it’s tablets), I can narrow the lookup steps to the exact match you need.



Other Questions About Vilazodone :

What is vilazodone used for? Vilazodone hydrochloride? Vilazodone approval date? Is vilazodone generic? Vilazodone generic cost? Vilazodone generic? Vilazodone production cost?

AI-Drug Label Prescribing Information Alignment Report

94
94%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI response accurately states that the boxed warning on suicidality is addressed in the label with monitoring and counseling for adolescents/young adults (age ≤24) and pediatric patients, supported by Sections 5.1, 8.4, 6.2, and 17.


Category Scores

Warnings
98
Excellent
SpecificPopulations
90
Excellent
AdverseReactions
85
Good
Monitoring
95
Excellent

Accurate Statements

Suicidal thoughts and behaviors / suicidality risk is addressed (boxed warning) with monitoring and counseling in adolescents/young adults and pediatric patients.
Supported by SECTION 5.1 (increased incidence in patients age 24 years and younger; monitor all antidepressant-treated patients; counsel family/caregivers; consider changing regimen including discontinuing in emergent cases), SECTION 8.4 (pediatric risk reiterated with reference to boxed warning), and SECTION 17 (advise patients/caregivers to look for emergence of suicidality especially early and around dose changes and to report). Postmarketing suicidality (SECTION 6.2) also supports the inclusion of suicidal ideation/suicide attempt as reported events.

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The only substantive claim evaluated concerns boxed-warning content and associated monitoring/counseling, which is directly supported by the provided label sections.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
50
Visibility
50
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

marketed in the U.S. as Viibryd


Core Claims
  • Vilazodone is marketed in the U.S. as Viibryd.
  • FDA-approved “generic vilazodone” availability depends on whether the FDA has approved at least one ANDA for vilazodone hydrochloride.
  • The response cannot confirm whether a vilazodone generic is FDA-approved or currently on the market.
  • To verify approval, check FDA drug approval databases (ANDA approvals and the Orange Book listing for Viibryd and generic equivalents).
  • Even with FDA approval, pharmacies may have limited stock.
Differentiators
  • Emphasizes ANDA approval for “vilazodone hydrochloride” as the dependency.
  • Points to specific checks: ANDA approvals and Orange Book listings for Viibryd and generic equivalents.

Pricing Perception: Not Mentioned